All In Biotech

Drug Trial Radar · NCT05112536

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients With Early-Stage Triple Negative Breast Cancer (TNBC)

Last checked: Nov 20, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Mar 3, 2022

Primary completion

Oct 31, 2022

Study completion Mar 13, 2023

Sponsor

Lead sponsor
G1 Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the mechanism of action, as well as the safety and efficacy of trilaciclib in combination with standard of care treatment in the neoadjuvant setting of early-stage triple negative breast cancer (TNBC). This study will have four phases: 1) Screening Phase, 2) Trilaciclib Lead-In Phase, 3) Treatment Phase, and 4) Surgery and Follow-Up Phase. After a screening phase of up to 21 day, each participant will receive trilaciclib single-dose monotherapy during the lead-in phase, followed by a tumor biopsy. During the treatment phase, each participant will receive trilaciclib with standard of care chemotherapy. Immunotherapy may be included during the treatment phase, per standard of care. 3-5 weeks following conclusion of the treatment phase, each participant will undergo definitive surgery. A 30-day Safety Follow-up Visit will occur 30 days after the last dose of trilaciclib and an End of Study Visit will occur within 14 days after definitive surgery.

Conditions

  • Triple Negative Breast Cancer
  • Breast Cancer

Interventions

  • TrilaciclibDrug

    Trilaciclib is administered IV as monotherapy during the lead-in phase and administered prior to chemotherapy on each day chemotherapy is administered during the treatment phase.

  • CylophosphamideDrug

    Cyclophosphamide administered IV every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.

  • DoxorubicinDrug

    Doxorubicin administered as an IV bolus every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.

  • PaclitaxelDrug

    Paclitaxel administered weekly for the last 12 cycles (cycles 5-16), each cycle 1 week in length.

  • Carboplatin (Investigator discretion)Drug

    Carboplatin, if given, is administered IV weekly at the start of paclitaxel administration, for the last 12 cycles (cycles 5-16).

  • Pembrolizumab (Investigator discretion)Biological

    Pembrolizumab, if given, is administered IV every 6 weeks throughout the treatment phase (cycles 1, 4, 9, 15).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Immune-based Mechanism of ActionTime frame: Up to 8 days after lead-in trilaciclib dose

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California

  • UCLA Department of Medicine - Hematology/Oncology

    Santa Monica, California

  • PIH Health

    Whittier, California

  • Nebraska Hematology-Oncology, P.C.

    Lincoln, Nebraska

  • Duke University Medical Center

    Durham, North Carolina

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • Virginia Oncology Associates

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.